Hepcidin

Portfolio Company Disc Medicine Enters Definitive Merger Agreement with Gemini Therapeutics

Retrieved on: 
Wednesday, August 10, 2022
Diamond, Chronic kidney disease, Sickle cell disease, Sodium- and chloride-dependent glycine transporter 1, Hepcidin, Erythropoietic porphyria, Inflammation, Industry, DBA, AbbVie, Microdeletion syndrome, Genetic disorder, Cancer, Medicine, Diamond–Blackfan anemia, Hope, Patient, TMPRSS6, Biotechnology, Degenerative disease, Disc, Anemia, Polycythemia, Iron overload, Ruxolitinib, Hematologic disease, Thalassemia, Hereditary haemochromatosis, Pharmaceutical industry, HJV

Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.

Key Points: 
  • Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders.
  • Disc is building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.
  • Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.
  • Disc has a clinical-stage development pipeline composed of investigational product candidates that affect heme biosynthesis and iron metabolism.

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Iron metabolism, Medical specialties, Clinical medicine, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Iron overload, Erythropoietin

Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.

Key Points: 
  • Poster presentation demonstrates that KER-050 had effects on multiple stages of erythroblast maturation (both early- and late-stage) and increased circulating erythropoietin in preclinical models.
  • We are pleased to be able to present multiple posters at this years EHA2021 Virtual Congress.
  • Our preclinical studies continue to elucidate the relationship between ALK2 inhibition, hepcidin and serum iron.
  • In addition, the data suggests that ALK2 inhibition has the potential to mobilize and reduce tissue iron in diseases of iron overload, said Jasbir S. Seehra, Ph.D., Chief Executive Officer of Keros.

2021 Market Report on Hepcidin Drugs in Development - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 3, 2021
Health, Pharmaceutical, Medical specialties, Branches of biology, Iron metabolism, Blood proteins, Hepatology, Peptide hormones, Hepcidin, Immune system, Hamp, Antimicrobial peptides, Liver, HEPC

The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report the pipeline Target constitutes close to 5 molecules.
  • Hepcidin is a protein encoded by the HAMP gene.
  • It also reviews key players involved in Hepcidin (Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP) targeted therapeutics development with respective active and dormant or discontinued projects.

Disc Medicine to Present at the European Hematology Association (EHA) 2021 Virtual Congress

Retrieved on: 
Monday, May 24, 2021
Hepatology, Hepcidin, Iron metabolism, EHA, European Hematology Association, Branches of biology, Medicine, Health care

CAMBRIDGE, Mass., May 24, 2021 /PRNewswire/ --Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association (EHA) 2021 Virtual Congress, which will be held from June 9-17.

Key Points: 
  • CAMBRIDGE, Mass., May 24, 2021 /PRNewswire/ --Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data of its hepcidin induction program will be presented at the upcoming European Hematology Association (EHA) 2021 Virtual Congress, which will be held from June 9-17.
  • Details of the presentations are as follows:
    The e-poster presentation will be made available as of Friday, June 11, 2021 (09:00 CEST) and will be accessible for on-demand viewing until August 15, 2021.
  • The abstract is currently available online on EHA2021 Virtual Congress Platform.
  • Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders.

Protagonist Therapeutics to Participate in the H.C. Wainwright Global Life Sciences Conference

Retrieved on: 
Tuesday, March 2, 2021
Iron metabolism, Hepatology, Hepcidin, Branches of biology

NEWARK, Calif., March 2, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C. Wainwright Global Life Sciences Conference taking place March 9 to March 10, 2021.

Key Points: 
  • NEWARK, Calif., March 2, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and will host one-on-one meetings with investors at the upcoming virtual H.C. Wainwright Global Life Sciences Conference taking place March 9 to March 10, 2021.
  • Time: Available on-demand starting at 7:00 a.m. EST
    Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development.
  • PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis.
  • PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease.

Protagonist Therapeutics to Participate in the SVB Leerink Virtual 10th Annual Global Healthcare Conference

Retrieved on: 
Tuesday, February 16, 2021
Iron metabolism, Hepatology, Hepcidin, SVB Leerink, Branches of biology, Companies

NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place February 22 to February 26, 2021.

Key Points: 
  • NEWARK, Calif., Feb. 16, 2021 /PRNewswire/ --Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at SVB Leerink Virtual 10th Annual Global Healthcare Conference taking place February 22 to February 26, 2021.
  • Protagonist Therapeutics is a clinical stage biopharmaceutical company with multiple peptide-based new chemical entities in different stages of development.
  • PTG-300 is an injectable hepcidin mimetic in a Phase 2 proof-of-concept clinical trial for polycythemia vera, and a separate Phase 2 clinical study for hereditary hemochromatosis.
  • PTG-200 is an orally delivered, gut-restricted, interleukin-23 receptor specific antagonist peptide in a Phase 2 clinical trial for Crohn's disease.

Protagonist Announces Updated Phase 2 Data Presented at ASH Annual Meeting Supporting Long Term Efficacy of Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

Retrieved on: 
Sunday, December 6, 2020
Medical specialties, Branches of biology, Hematopathology, Hematology, Iron metabolism, Hepatology, Hepcidin, Polycythemia vera, Polycythemia, Iron deficiency, Hematologic disease

The data were presented in an oral presentation today at the 62nd American Academy of Hematology annual meeting, being held December 5-8, 2020.

Key Points: 
  • The data were presented in an oral presentation today at the 62nd American Academy of Hematology annual meeting, being held December 5-8, 2020.
  • Treatment with PTG-300 was also shown to reverse iron deficiency, a serious side effect of regular therapeutic phlebotomies as a treatment for PV.
  • PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.
  • Any forward-looking statements that we make in this press release speak only as of the date of this press release.

Protagonist to Host Conference Call and Webcast to Provide a Research Update on December 9, 2020

Retrieved on: 
Monday, November 30, 2020
Hematopathology, Blood, Medical specialties, Branches of biology, Iron metabolism, Hepatology, Hepcidin, Polycythemia vera, Polycythemia, Newark, New Jersey, NASDAQ, Rotary dial

NEWARK, Calif., Nov. 30, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Corporate update at 8:30 a.m. EST on December 9, 2020.

Key Points: 
  • NEWARK, Calif., Nov. 30, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will host a conference call to provide a research and development (R&D) and Corporate update at 8:30 a.m. EST on December 9, 2020.
  • To access the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and refer to conference ID number 8794865.
  • A live and archived webcast will also be accessible in the Investors section of the Company's website at www.protagonist-inc.com .
  • PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.

Protagonist Therapeutics to Present at the Virtual Piper Sandler 32nd Annual Healthcare Conference

Retrieved on: 
Wednesday, November 25, 2020
Hepatology, Hepcidin, Iron metabolism, Piper Sandler Companies, HEPC, Branches of biology, Companies

NEWARK, Calif., Nov. 25, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30 to December 3, 2020.

Key Points: 
  • NEWARK, Calif., Nov. 25, 2020 /PRNewswire/ --Protagonist Therapeutics, Inc. (NASDAQ: PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30 to December 3, 2020.
  • The presentation will be available for registered attendees via the Piper Sandler conference site until December 3, 2020, and will also be available November 30, 2020, by visiting the Investors section of the Protagonist Therapeutics website at http://investors.protagonist-inc.com/ .
  • Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based therapeutics to address significant unmet medical needs and transform existing treatment paradigms for patients.
  • PTG-300 is an injectable hepcidin mimetic in development for the treatment of polycythemia vera and other blood disorders.

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

Retrieved on: 
Monday, November 23, 2020
Branches of biology, Anatomy, Hepatology, Hepcidin, Iron metabolism, Erythropoiesis, Hematology

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ --Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ --Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.
  • A pre-recorded presentation by John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will be available beginning on Monday, November 23 at 10:00 am Eastern Standard Time.
  • A link to the presentation will be provided in the "News & Events" section of Disc Medicine's website at www.discmedicine.com .
  • Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases.